PolyPid Ltd.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Medical Devices
    • Biomaterials
  • Biotechnology
See more in Biomedtracker

Latest on PolyPid Ltd.

Scrip

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

Following a missed Phase III endpoint in 2022 , PolyPid has reported positive top-line results from its Phase III SHIELD II trial with D-PLEX100 for the prevention of surgical site infections (SSIs)

Scrip

Scrip Asks… What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering

 
• By Eleanor Malone

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Scrip

Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Scrip

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

 
• By Mandy Jackson

Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been